BindingDB logo
myBDB logout

Patent code US10457703

Compile Data Set for Download or QSAR

Found 240 hits of Enzyme Inhibition Constant Data   
Target/Host
(Institution)
LigandTarget/Host
Links
Ligand
Links
Trg + Lig
Links
Ki
nM
ΔG°
kJ/mole
IC50
nM
Kd
nM
EC50/IC50
nM
koff
s-1
kon
M-1s-1
pHTemp
°C
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419506
PNG
(US10457703, Example 168)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOC(=O)N[C@H]4CCCC[C@@H]4O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C32H55NO5/c1-5-21-25-18-20(34)12-15-32(25,4)24-13-16-31(3)22(10-11-23(31)28(24)29(21)36)19(2)14-17-38-30(37)33-26-8-6-7-9-27(26)35/h19-29,34-36H,5-18H2,1-4H3,(H,33,37)/t19-,20-,21-,22-,23+,24+,25+,26+,27+,28+,29-,31-,32-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a 55n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419515
PNG
(US10457703, Example 177)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOC(=O)NCCC4CC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C31H53NO4/c1-5-22-26-18-21(33)10-14-31(26,4)25-11-15-30(3)23(8-9-24(30)27(25)28(22)34)19(2)13-17-36-29(35)32-16-12-20-6-7-20/h19-28,33-34H,5-18H2,1-4H3,(H,32,35)/t19-,21-,22-,23-,24+,25+,26+,27+,28-,30-,31-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a 55n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419322
PNG
(US10457703, Example 5)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)COC(=O)NS(=O)(=O)c4ccc(C)cc4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C32H49NO6S/c1-6-23-27-17-21(34)13-15-32(27,5)26-14-16-31(4)24(11-12-25(31)28(26)29(23)35)20(3)18-39-30(36)33-40(37,38)22-9-7-19(2)8-10-22/h7-10,20-21,23-29,34-35H,6,11-18H2,1-5H3,(H,33,36)/t20-,21-,23-,24-,25+,26+,27+,28+,29-,31-,32-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a 55n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419324
PNG
(US10457703, Example 7)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)COC(=O)NS(=O)(=O)N(C)C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C27H48N2O6S/c1-7-18-22-14-17(30)10-12-27(22,4)21-11-13-26(3)19(8-9-20(26)23(21)24(18)31)16(2)15-35-25(32)28-36(33,34)29(5)6/h16-24,30-31H,7-15H2,1-6H3,(H,28,32)/t16-,17-,18-,19-,20+,21+,22+,23+,24-,26-,27-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419521
PNG
(US10457703, Example 183)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOC(=O)N4CCC(CO)(CCl)CC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C33H56ClNO5/c1-5-23-27-18-22(37)8-11-32(27,4)26-9-12-31(3)24(6-7-25(31)28(26)29(23)38)21(2)10-17-40-30(39)35-15-13-33(19-34,20-36)14-16-35/h21-29,36-38H,5-20H2,1-4H3/t21-,22-,23-,24-,25+,26+,27+,28+,29-,31-,32-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a<10n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419329
PNG
(US10457703, Example 12)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)COC(=O)NS(=O)(=O)c4ccc5ccccc5c4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C35H49NO6S/c1-5-26-30-19-24(37)14-16-35(30,4)29-15-17-34(3)27(12-13-28(34)31(29)32(26)38)21(2)20-42-33(39)36-43(40,41)25-11-10-22-8-6-7-9-23(22)18-25/h6-11,18,21,24,26-32,37-38H,5,12-17,19-20H2,1-4H3,(H,36,39)/t21-,24-,26-,27-,28+,29+,30+,31+,32-,34-,35-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a<10n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419535
PNG
(US10457703, Example 197)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOC(=O)Nc4ccc5ccccc5c4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C36H51NO4/c1-5-27-31-21-26(38)14-17-36(31,4)30-15-18-35(3)28(12-13-29(35)32(30)33(27)39)22(2)16-19-41-34(40)37-25-11-10-23-8-6-7-9-24(23)20-25/h6-11,20,22,26-33,38-39H,5,12-19,21H2,1-4H3,(H,37,40)/t22-,26-,27-,28-,29+,30+,31+,32+,33-,35-,36-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419538
PNG
(US10457703, Example 200)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)COC(=O)N4CCC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C28H47NO4/c1-5-19-23-15-18(30)9-11-28(23,4)22-10-12-27(3)20(7-8-21(27)24(22)25(19)31)17(2)16-33-26(32)29-13-6-14-29/h17-25,30-31H,5-16H2,1-4H3/t17-,18-,19-,20-,21+,22+,23+,24+,25-,27-,28-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419540
PNG
(US10457703, Example 202)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOC(=O)N4CCC(CO)CC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C32H55NO5/c1-5-23-27-18-22(35)8-13-32(27,4)26-9-14-31(3)24(6-7-25(31)28(26)29(23)36)20(2)12-17-38-30(37)33-15-10-21(19-34)11-16-33/h20-29,34-36H,5-19H2,1-4H3/t20-,22-,23-,24-,25+,26+,27+,28+,29-,31-,32-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a 55n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419353
PNG
(US10457703, Example 36)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)COC(=O)NS(=O)(=O)c4ccc(cc4)-c4ncccn4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C35H49N3O6S/c1-5-25-29-19-23(39)13-15-35(29,4)28-14-16-34(3)26(11-12-27(34)30(28)31(25)40)21(2)20-44-33(41)38-45(42,43)24-9-7-22(8-10-24)32-36-17-6-18-37-32/h6-10,17-18,21,23,25-31,39-40H,5,11-16,19-20H2,1-4H3,(H,38,41)/t21-,23-,25-,26-,27+,28+,29+,30+,31-,34-,35-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a<10n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419357
PNG
(US10457703, Example 44-a)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)COC(=O)NS(=O)(=O)c4ccc(cc4)N4C5CCC4CC5)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C37H56N2O6S/c1-5-28-32-20-26(40)16-18-37(32,4)31-17-19-36(3)29(14-15-30(36)33(31)34(28)41)22(2)21-45-35(42)38-46(43,44)27-12-10-25(11-13-27)39-23-6-7-24(39)9-8-23/h10-13,22-24,26,28-34,40-41H,5-9,14-21H2,1-4H3,(H,38,42)/t22-,23?,24?,26-,28-,29-,30+,31+,32+,33+,34-,36-,37-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a<10n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419359
PNG
(US10457703, Example 44-c)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)COC(=O)NS(=O)(=O)c4ccc(nc4)N4CCC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C33H51N3O6S/c1-5-23-27-17-21(37)11-13-33(27,4)26-12-14-32(3)24(8-9-25(32)29(26)30(23)38)20(2)19-42-31(39)35-43(40,41)22-7-10-28(34-18-22)36-15-6-16-36/h7,10,18,20-21,23-27,29-30,37-38H,5-6,8-9,11-17,19H2,1-4H3,(H,35,39)/t20-,21-,23-,24-,25+,26+,27+,29+,30-,32-,33-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a<10n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419361
PNG
(US10457703, Example 44-e)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)COC(=O)NS(=O)(=O)c4ccc(cc4)-n4cnnn4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C32H47N5O6S/c1-5-23-27-16-21(38)12-14-32(27,4)26-13-15-31(3)24(10-11-25(31)28(26)29(23)39)19(2)17-43-30(40)34-44(41,42)22-8-6-20(7-9-22)37-18-33-35-36-37/h6-9,18-19,21,23-29,38-39H,5,10-17H2,1-4H3,(H,34,40)/t19-,21-,23-,24-,25+,26+,27+,28+,29-,31-,32-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a 55n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419362
PNG
(US10457703, Example 44-f)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)COC(=O)NS(=O)(=O)c4ccc(cc4)-n4cncn4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C33H48N4O6S/c1-5-24-28-16-22(38)12-14-33(28,4)27-13-15-32(3)25(10-11-26(32)29(27)30(24)39)20(2)17-43-31(40)36-44(41,42)23-8-6-21(7-9-23)37-19-34-18-35-37/h6-9,18-20,22,24-30,38-39H,5,10-17H2,1-4H3,(H,36,40)/t20-,22-,24-,25-,26+,27+,28+,29+,30-,32-,33-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a<10n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419377
PNG
(US10457703, Example 49)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOC(=O)NS(=O)(=O)C4(C)CC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C30H51NO6S/c1-6-20-24-17-19(32)9-12-30(24,5)23-10-13-29(4)21(7-8-22(29)25(23)26(20)33)18(2)11-16-37-27(34)31-38(35,36)28(3)14-15-28/h18-26,32-33H,6-17H2,1-5H3,(H,31,34)/t18-,19-,20-,21-,22+,23+,24+,25+,26-,29-,30-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a<10n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419378
PNG
(US10457703, Example 50)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOC(=O)NS(=O)(=O)N(C)C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C28H50N2O6S/c1-7-19-23-16-18(31)10-13-28(23,4)22-11-14-27(3)20(8-9-21(27)24(22)25(19)32)17(2)12-15-36-26(33)29-37(34,35)30(5)6/h17-25,31-32H,7-16H2,1-6H3,(H,29,33)/t17-,18-,19-,20-,21+,22+,23+,24+,25-,27-,28-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a<10n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419385
PNG
(US10457703, Example 57)
Show SMILES CCCCS(=O)(=O)NC(=O)OCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@H](O)[C@H](CC)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
Show InChI InChI=1/C30H53NO6S/c1-6-8-17-38(35,36)31-28(34)37-16-13-19(3)22-9-10-23-26-24(12-15-29(22,23)4)30(5)14-11-20(32)18-25(30)21(7-2)27(26)33/h19-27,32-33H,6-18H2,1-5H3,(H,31,34)/t19-,20-,21-,22-,23+,24+,25+,26+,27-,29-,30-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a<10n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419403
PNG
(US10457703, Example 75)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOC(=O)NS(=O)(=O)C(C)C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C29H51NO6S/c1-7-20-24-16-19(31)10-13-29(24,6)23-11-14-28(5)21(8-9-22(28)25(23)26(20)32)18(4)12-15-36-27(33)30-37(34,35)17(2)3/h17-26,31-32H,7-16H2,1-6H3,(H,30,33)/t18-,19-,20-,21-,22+,23+,24+,25+,26-,28-,29-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a<10n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419405
PNG
(US10457703, Example 77)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOC(=O)NS(=O)(=O)c4ccccc4OC(F)(F)F)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C33H48F3NO7S/c1-5-21-25-18-20(38)12-15-32(25,4)24-13-16-31(3)22(10-11-23(31)28(24)29(21)39)19(2)14-17-43-30(40)37-45(41,42)27-9-7-6-8-26(27)44-33(34,35)36/h6-9,19-25,28-29,38-39H,5,10-18H2,1-4H3,(H,37,40)/t19-,20-,21-,22-,23+,24+,25+,28+,29-,31-,32-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a 55n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419407
PNG
(US10457703, Example 79)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOC(=O)NS(=O)(=O)c4ccc(cc4)C(F)(F)F)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C33H48F3NO6S/c1-5-23-27-18-21(38)12-15-32(27,4)26-13-16-31(3)24(10-11-25(31)28(26)29(23)39)19(2)14-17-43-30(40)37-44(41,42)22-8-6-20(7-9-22)33(34,35)36/h6-9,19,21,23-29,38-39H,5,10-18H2,1-4H3,(H,37,40)/t19-,21-,23-,24-,25+,26+,27+,28+,29-,31-,32-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a<10n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419412
PNG
(US10457703, Example 84)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOC(=O)NS(=O)(=O)c4ccccc4OC)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C33H51NO7S/c1-6-22-26-19-21(35)13-16-33(26,4)25-14-17-32(3)23(11-12-24(32)29(25)30(22)36)20(2)15-18-41-31(37)34-42(38,39)28-10-8-7-9-27(28)40-5/h7-10,20-26,29-30,35-36H,6,11-19H2,1-5H3,(H,34,37)/t20-,21-,22-,23-,24+,25+,26+,29+,30-,32-,33-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a<10n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419422
PNG
(US10457703, Example 94)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOC(=O)NS(=O)(=O)c4ccc(OC)c(F)c4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C33H50FNO7S/c1-6-22-26-17-20(36)11-14-33(26,4)25-12-15-32(3)23(8-9-24(32)29(25)30(22)37)19(2)13-16-42-31(38)35-43(39,40)21-7-10-28(41-5)27(34)18-21/h7,10,18-20,22-26,29-30,36-37H,6,8-9,11-17H2,1-5H3,(H,35,38)/t19-,20-,22-,23-,24+,25+,26+,29+,30-,32-,33-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a<10n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419425
PNG
(US10457703, Example 97)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOC(=O)NS(C)(=O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C27H47NO6S/c1-6-18-22-15-17(29)9-12-27(22,4)21-10-13-26(3)19(7-8-20(26)23(21)24(18)30)16(2)11-14-34-25(31)28-35(5,32)33/h16-24,29-30H,6-15H2,1-5H3,(H,28,31)/t16-,17-,18-,19-,20+,21+,22+,23+,24-,26-,27-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a 55n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419430
PNG
(US10457703, Example 102)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOC(=O)NS(=O)(=O)c4ccc(F)c(F)c4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C32H47F2NO6S/c1-5-21-25-16-19(36)10-13-32(25,4)24-11-14-31(3)22(7-8-23(31)28(24)29(21)37)18(2)12-15-41-30(38)35-42(39,40)20-6-9-26(33)27(34)17-20/h6,9,17-19,21-25,28-29,36-37H,5,7-8,10-16H2,1-4H3,(H,35,38)/t18-,19-,21-,22-,23+,24+,25+,28+,29-,31-,32-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a<10n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419432
PNG
(US10457703, Example 104-a)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOC(=O)NS(=O)(=O)C4CCCCC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C32H55NO6S/c1-5-23-27-19-21(34)13-16-32(27,4)26-14-17-31(3)24(11-12-25(31)28(26)29(23)35)20(2)15-18-39-30(36)33-40(37,38)22-9-7-6-8-10-22/h20-29,34-35H,5-19H2,1-4H3,(H,33,36)/t20-,21-,23-,24-,25+,26+,27+,28+,29-,31-,32-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a<10n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419442
PNG
(US10457703, Example 104-k)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOC(=O)NS(=O)(=O)c4ccc(OC(F)(F)F)c(F)c4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C33H47F4NO7S/c1-5-21-25-16-19(39)10-13-32(25,4)24-11-14-31(3)22(7-8-23(31)28(24)29(21)40)18(2)12-15-44-30(41)38-46(42,43)20-6-9-27(26(34)17-20)45-33(35,36)37/h6,9,17-19,21-25,28-29,39-40H,5,7-8,10-16H2,1-4H3,(H,38,41)/t18-,19-,21-,22-,23+,24+,25+,28+,29-,31-,32-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a 55n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419454
PNG
(US10457703, Example 116)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCCOC(=O)NS(=O)(=O)c4ccc(cc4)-c4ccccc4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C39H55NO6S/c1-5-30-34-24-28(41)19-21-39(34,4)33-20-22-38(3)31(17-18-32(38)35(33)36(30)42)25(2)10-9-23-46-37(43)40-47(44,45)29-15-13-27(14-16-29)26-11-7-6-8-12-26/h6-8,11-16,25,28,30-36,41-42H,5,9-10,17-24H2,1-4H3,(H,40,43)/t25-,28-,30-,31-,32+,33+,34+,35+,36-,38-,39-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419455
PNG
(US10457703, Example 117)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCCOC(=O)NS(=O)(=O)C(C)(C)C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C31H55NO6S/c1-8-21-25-18-20(33)13-15-31(25,7)24-14-16-30(6)22(11-12-23(30)26(24)27(21)34)19(2)10-9-17-38-28(35)32-39(36,37)29(3,4)5/h19-27,33-34H,8-18H2,1-7H3,(H,32,35)/t19-,20-,21-,22-,23+,24+,25+,26+,27-,30-,31-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a 55n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419464
PNG
(US10457703, Example 126)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCCOC(=O)NC4CCCCC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C33H57NO4/c1-5-24-28-20-23(35)15-17-33(28,4)27-16-18-32(3)25(13-14-26(32)29(27)30(24)36)21(2)10-9-19-38-31(37)34-22-11-7-6-8-12-22/h21-30,35-36H,5-20H2,1-4H3,(H,34,37)/t21-,23-,24-,25-,26+,27+,28+,29+,30-,32-,33-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419469
PNG
(US10457703, Example 131)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCCOC(=O)N4CCCC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C31H53NO4/c1-5-22-26-19-21(33)12-14-31(26,4)25-13-15-30(3)23(10-11-24(30)27(25)28(22)34)20(2)9-8-18-36-29(35)32-16-6-7-17-32/h20-28,33-34H,5-19H2,1-4H3/t20-,21-,22-,23-,24+,25+,26+,27+,28-,30-,31-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a 55n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419472
PNG
(US10457703, Example 134)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOC(=O)NC4CCCC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C31H53NO4/c1-5-22-26-18-21(33)12-15-31(26,4)25-13-16-30(3)23(10-11-24(30)27(25)28(22)34)19(2)14-17-36-29(35)32-20-8-6-7-9-20/h19-28,33-34H,5-18H2,1-4H3,(H,32,35)/t19-,21-,22-,23-,24+,25+,26+,27+,28-,30-,31-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a 55n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419484
PNG
(US10457703, Example 146)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOC(=O)N4CCCCC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C31H53NO4/c1-5-22-26-19-21(33)11-14-31(26,4)25-12-15-30(3)23(9-10-24(30)27(25)28(22)34)20(2)13-18-36-29(35)32-16-7-6-8-17-32/h20-28,33-34H,5-19H2,1-4H3/t20-,21-,22-,23-,24+,25+,26+,27+,28-,30-,31-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a<10n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419492
PNG
(US10457703, Example 154)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOC(=O)N[C@@H](C(C)C)C(=O)OC)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C32H55NO6/c1-8-21-25-17-20(34)11-14-32(25,6)24-12-15-31(5)22(9-10-23(31)26(24)28(21)35)19(4)13-16-39-30(37)33-27(18(2)3)29(36)38-7/h18-28,34-35H,8-17H2,1-7H3,(H,33,37)/t19-,20-,21-,22-,23+,24+,25+,26+,27+,28-,31-,32-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a 55n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419517
PNG
(US10457703, Example 179)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOC(=O)N(CCO)CCO)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C30H53NO6/c1-5-21-25-18-20(34)8-11-30(25,4)24-9-12-29(3)22(6-7-23(29)26(24)27(21)35)19(2)10-17-37-28(36)31(13-15-32)14-16-33/h19-27,32-35H,5-18H2,1-4H3/t19-,20-,21-,22-,23+,24+,25+,26+,27-,29-,30-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a 55n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419319
PNG
(US10457703, Example 1)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCCOC(=O)NS(=O)(=O)c4ccc(C)cc4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C34H53NO6S/c1-6-25-29-20-23(36)15-17-34(29,5)28-16-18-33(4)26(13-14-27(33)30(28)31(25)37)22(3)8-7-19-41-32(38)35-42(39,40)24-11-9-21(2)10-12-24/h9-12,22-23,25-31,36-37H,6-8,13-20H2,1-5H3,(H,35,38)/t22-,23-,25-,26-,27+,28+,29+,30+,31-,33-,34-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a 55n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419527
PNG
(US10457703, Example 189)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOC(=O)NCc4ccc(cc4)C(C)(C)C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C37H59NO4/c1-8-27-31-21-26(39)15-18-37(31,7)30-16-19-36(6)28(13-14-29(36)32(30)33(27)40)23(2)17-20-42-34(41)38-22-24-9-11-25(12-10-24)35(3,4)5/h9-12,23,26-33,39-40H,8,13-22H2,1-7H3,(H,38,41)/t23-,26-,27-,28-,29+,30+,31+,32+,33-,36-,37-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419529
PNG
(US10457703, Example 191)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOC(=O)Nc4ccccc4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C32H49NO4/c1-5-23-27-19-22(34)13-16-32(27,4)26-14-17-31(3)24(11-12-25(31)28(26)29(23)35)20(2)15-18-37-30(36)33-21-9-7-6-8-10-21/h6-10,20,22-29,34-35H,5,11-19H2,1-4H3,(H,33,36)/t20-,22-,23-,24-,25+,26+,27+,28+,29-,31-,32-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419530
PNG
(US10457703, Example 192)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOC(=O)NC(C)(C)C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C30H53NO4/c1-8-20-24-17-19(32)11-14-30(24,7)23-12-15-29(6)21(9-10-22(29)25(23)26(20)33)18(2)13-16-35-27(34)31-28(3,4)5/h18-26,32-33H,8-17H2,1-7H3,(H,31,34)/t18-,19-,20-,21-,22+,23+,24+,25+,26-,29-,30-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419325
PNG
(US10457703, Example 8)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)COC(=O)NS(=O)(=O)C4CCCCC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C31H53NO6S/c1-5-22-26-17-20(33)13-15-31(26,4)25-14-16-30(3)23(11-12-24(30)27(25)28(22)34)19(2)18-38-29(35)32-39(36,37)21-9-7-6-8-10-21/h19-28,33-34H,5-18H2,1-4H3,(H,32,35)/t19-,20-,22-,23-,24+,25+,26+,27+,28-,30-,31-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a 55n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419330
PNG
(US10457703, Example 13)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)COC(=O)NS(=O)(=O)N4CCCC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C29H50N2O6S/c1-5-20-24-16-19(32)10-12-29(24,4)23-11-13-28(3)21(8-9-22(28)25(23)26(20)33)18(2)17-37-27(34)30-38(35,36)31-14-6-7-15-31/h18-26,32-33H,5-17H2,1-4H3,(H,30,34)/t18-,19-,20-,21-,22+,23+,24+,25+,26-,28-,29-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a 55n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419332
PNG
(US10457703, Example 15)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)COC(=O)NS(=O)(=O)c4ccc(nc4)N4CCOCC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C34H53N3O7S/c1-5-24-28-18-22(38)10-12-34(28,4)27-11-13-33(3)25(7-8-26(33)30(27)31(24)39)21(2)20-44-32(40)36-45(41,42)23-6-9-29(35-19-23)37-14-16-43-17-15-37/h6,9,19,21-22,24-28,30-31,38-39H,5,7-8,10-18,20H2,1-4H3,(H,36,40)/t21-,22-,24-,25-,26+,27+,28+,30+,31-,33-,34-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a<10n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419533
PNG
(US10457703, Example 195 | US10457703, Example 196)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOC(=O)NC4CCCC4O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C31H53NO5/c1-5-20-24-17-19(33)11-14-31(24,4)23-12-15-30(3)21(9-10-22(30)27(23)28(20)35)18(2)13-16-37-29(36)32-25-7-6-8-26(25)34/h18-28,33-35H,5-17H2,1-4H3,(H,32,36)/t18-,19-,20-,21-,22+,23+,24+,25?,26?,27+,28-,30-,31-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a<10n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419537
PNG
(US10457703, Example 199)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)COC(=O)NC4CCCCC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C31H53NO4/c1-5-22-26-17-21(33)13-15-31(26,4)25-14-16-30(3)23(11-12-24(30)27(25)28(22)34)19(2)18-36-29(35)32-20-9-7-6-8-10-20/h19-28,33-34H,5-18H2,1-4H3,(H,32,35)/t19-,21-,22-,23-,24+,25+,26+,27+,28-,30-,31-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a 550n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419545
PNG
(US10457703, Example 207)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOC(=O)N[C@@H]4CCC[C@H]4O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C31H53NO5/c1-5-20-24-17-19(33)11-14-31(24,4)23-12-15-30(3)21(9-10-22(30)27(23)28(20)35)18(2)13-16-37-29(36)32-25-7-6-8-26(25)34/h18-28,33-35H,5-17H2,1-4H3,(H,32,36)/t18-,19-,20-,21-,22+,23+,24+,25-,26-,27+,28-,30-,31-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a 55n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419344
PNG
(US10457703, Example 27)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)COC(=O)NS(=O)(=O)c4ccc(s4)-c4ccc(cc4)C(F)(F)F)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C36H48F3NO6S2/c1-5-24-28-18-23(41)14-16-35(28,4)27-15-17-34(3)25(10-11-26(34)31(27)32(24)42)20(2)19-46-33(43)40-48(44,45)30-13-12-29(47-30)21-6-8-22(9-7-21)36(37,38)39/h6-9,12-13,20,23-28,31-32,41-42H,5,10-11,14-19H2,1-4H3,(H,40,43)/t20-,23-,24-,25-,26+,27+,28+,31+,32-,34-,35-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a 55n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419550
PNG
(US10457703, Example 212)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOC(=O)N4CC[C@@H](CO)C4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C31H53NO5/c1-5-22-26-16-21(34)8-12-31(26,4)25-9-13-30(3)23(6-7-24(30)27(25)28(22)35)19(2)11-15-37-29(36)32-14-10-20(17-32)18-33/h19-28,33-35H,5-18H2,1-4H3/t19-,20-,21-,22-,23-,24+,25+,26+,27+,28-,30-,31-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a<10n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419555
PNG
(US10457703, Example 217)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOC(=O)N4CCC(CC)(CO)CC4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C34H59NO5/c1-6-24-28-20-23(37)10-13-33(28,5)27-11-14-32(4)25(8-9-26(32)29(27)30(24)38)22(3)12-19-40-31(39)35-17-15-34(7-2,21-36)16-18-35/h22-30,36-38H,6-21H2,1-5H3/t22-,23-,24-,25-,26+,27+,28+,29+,30-,32-,33-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a<10n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419369
PNG
(US10457703, Example 44-m)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)COC(=O)NS(=O)(=O)c4ccc(nc4)-n4ccnc4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C33H48N4O6S/c1-5-23-27-16-21(38)10-12-33(27,4)26-11-13-32(3)24(7-8-25(32)29(26)30(23)39)20(2)18-43-31(40)36-44(41,42)22-6-9-28(35-17-22)37-15-14-34-19-37/h6,9,14-15,17,19-21,23-27,29-30,38-39H,5,7-8,10-13,16,18H2,1-4H3,(H,36,40)/t20-,21-,23-,24-,25+,26+,27+,29+,30-,32-,33-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a<10n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419372
PNG
(US10457703, Example 44-p)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)COC(=O)NS(=O)(=O)c4ccc(cc4)-c4ncco4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C34H48N2O7S/c1-5-24-28-18-22(37)12-14-34(28,4)27-13-15-33(3)25(10-11-26(33)29(27)30(24)38)20(2)19-43-32(39)36-44(40,41)23-8-6-21(7-9-23)31-35-16-17-42-31/h6-9,16-17,20,22,24-30,37-38H,5,10-15,18-19H2,1-4H3,(H,36,39)/t20-,22-,24-,25-,26+,27+,28+,29+,30-,33-,34-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a<10n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Bile acid receptor FXR


(Homo sapiens (Human))
BDBM419374
PNG
(US10457703, Example 46)
Show SMILES CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOC(=O)NS(=O)(=O)c4ccc(F)cc4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
Show InChI InChI=1/C32H48FNO6S/c1-5-23-27-18-21(35)12-15-32(27,4)26-13-16-31(3)24(10-11-25(31)28(26)29(23)36)19(2)14-17-40-30(37)34-41(38,39)22-8-6-20(33)7-9-22/h6-9,19,21,23-29,35-36H,5,10-18H2,1-4H3,(H,34,37)/t19-,21-,23-,24-,25+,26+,27+,28+,29-,31-,32-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
UniChem
US Patent
n/an/an/an/a<10n/an/an/an/a



Enanta Pharmaceuticals, Inc.

US Patent


Assay Description
Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit...


US Patent US10457703 (2019)

More data for this
Ligand-Target Pair
Displayed 1 to 50 (of 240 total )  |  Next  |  Last  >>
* indicates data uncertainty>20%